These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29454708)

  • 21. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin.
    Pagani M; Bonadonna P
    Anticancer Res; 2014 Jan; 34(1):537-40. PubMed ID: 24403513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
    Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
    Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study.
    Haine AI; Notenboom CMAW; Tan LVP; Ruiter R; van der Deure WM
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00985. PubMed ID: 35811355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
    Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
    Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergic-like Hypersensitivity Reactions to Gadolinium-based Contrast Agents: An 8-year Cohort Study of 154 539 Patients.
    Ahn YH; Kang DY; Park SB; Kim HH; Kim HJ; Park GY; Yoon SH; Choi YH; Lee SY; Kang HR
    Radiology; 2022 May; 303(2):329-336. PubMed ID: 35191737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersensitivity Reactions to Iodinated Contrast Media: A Multicenter Study of 196 081 Patients.
    Cha MJ; Kang DY; Lee W; Yoon SH; Choi YH; Byun JS; Lee J; Kim YH; Choo KS; Cho BS; Jeon KN; Jung JW; Kang HR
    Radiology; 2019 Oct; 293(1):117-124. PubMed ID: 31478801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
    Barroso-Sousa R; Vaz-Luis I; Di Meglio A; Hu J; Li T; Rees R; Sinclair N; Milisits L; Leone JP; Constantine M; Faggen M; Briccetti F; Block C; Partridge A; Burstein H; Waks AG; Tayob N; Trippa L; Tolaney SM; Hassett MJ; Winer EP; Lin NU
    Oncologist; 2021 Nov; 26(11):927-933. PubMed ID: 34472667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and Risk Factors of Immediate Hypersensitivity Reactions Associated With Low-Osmolar Iodinated Contrast Media: A Longitudinal Study Based on a Real-Time Monitoring System.
    Lee SY; Kang DY; Kim JY; Yoon SH; Choi YH; Lee W; Cho SH; Kang HR
    J Investig Allergol Clin Immunol; 2019; 29(6):444-450. PubMed ID: 30676320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
    Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
    Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review.
    Barbin F; Ghidini M; Panichi A; Tomasello G; Bareggi C; Galassi B; Denaro N; Ruatta F; Cauchi C; Rossino MG; Garrone O
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences].
    Rezáč A; Jílek P; Rezáčová V; Skapinec P; Sedláková I; Tošner J; Spaček J
    Ceska Gynekol; 2013 Dec; 78(6):514-21. PubMed ID: 24372428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
    Yun H; Xie F; Beyl RN; Chen L; Lewis JD; Saag KG; Curtis JR
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1526-1534. PubMed ID: 27813327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions.
    Tampellini M; Benedetto S; Rubatto E; Baratelli C; DI Scipio F; Pirro E; Brizzi MP; Sonetto C; DI Maio M; Berta GN; Scagliotti GV
    Anticancer Res; 2016 Oct; 36(10):5163-5170. PubMed ID: 27798876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).
    Strobbe G; Gaboriau L; Abelé M; Villain A; Aelbrecht-Meurisse C; Carnot A; Le Deley MC; Léguillette C; Feutry F; Sakji I; Marliot G
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1229-1238. PubMed ID: 37438439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?
    Aoyama T; Takano M; Miyamoto M; Yoshikawa T; Soyama H; Kato K; Ishibashi H; Iwahashi H; Nakatsuka M; Yajima I; Shimizu Y; Aizawa Y; Suguchi Y; Moriiwa M; Goto T; Sasa H; Nagaoka I; Tsuda H; Furuya K
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):65-69. PubMed ID: 28493032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The Incidence and Management of Hypersensitivity and Infusion Reactions in an Outpatient Chemotherapy Center].
    Sekine H; Akaiwa A; Onozawa Y; Kinjo T; Nakamura H; Nakamura R; Nawa M; Yoshida S; Araki N; Iizuka M; Shimizu H; Sunaga N; Tsukamoto N
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1625-1629. PubMed ID: 30449851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.